Motixafortide with G-CSF to collect stem cells in multiple myeloma

Trial details

Who runs it

Guangzhou Gloria Biosciences Co., Ltd.

Trial code

NCT06514508

Record updated

14 September 2026

Original description

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.Read full original descriptionShow less

A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.

Inclusion: (Limit: 15,000 characters); Patients must have a signed study informed consent prior to entering the study; Patients must be between the ages of 18 and 78 years; Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria; At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization; Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator's discretion; The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR); Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Adequate organ function at screening; Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

Exclusion: Previous history of autologous or allogeneic-HCT; Failed previous HSC collections or collection attempts; Received >6 cycles lifetime exposure to thalidomide or lenalidomide; Received >8 cycles of alkylating agent combinations; Received > 6 cycles of melphalan; Received prior treatment with radioimmunotherapy (e.g. radionuclides); Received prior treatment with venetoclax; Plans to receive maintenance treatment within 60 days post- transplantation (e.g.lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.); Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted; Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug; A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF, or other agents used in the study; Has an active or uncontrolled infection requiring systemic therapy; Has a known additional malignancy that is progressing or requires active treatment; History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death; Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or NYHA Heart Failure Class >2; Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities; Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive); Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:; Dexamethasone: 7 days; Thalidomide: 7 days; Lenalidomide: 7 days; Pamolidomide: 7 days; Bortezomib: 7 days; Carfilzomib: 7 days; G-CSF: 14 days; GM-CSF or Neulasta®: 21 days; Erythropoietin or erythrocyte stimulating agents: 30 days; Eltrombopag, romiplostim or platelet stimulating agents: 30 days; Carmustine (BCNU): 42 days/6 weeks; Daratumumab or any other anti-CD38: 28 days; Ixazomib: 7 day; Personal history or family history of Long QT Syndrome or Torsade de Pointes; Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator; Known active CNS metastases or carcinomatous meningitis; O2 saturation < 92% (on room air); ECG at screening showing QTcF > 470 msec and/or PR > 280 msec.

ClinicalTrials.gov NCT06514508